Hmmm, still no Eli Lilly report or any report from the ACR management. I hope I'm wrong but I'm wondering is the company lacking leadership with no M.D. I'm assuming that the Chairman is taking an active role in the company but whoever is in leadership is letting the shorters affect the shareprice once again. As other Hot Copper posters have commented over the past weeks the shorters have increased their attack on the share price and today was quite an example. Strong leadership is needed, sure we are all waiting for news of the patent extension but if Lilly's quarterly report is not material at this stage I beg to say I don't know what is.
ACR Price at posting:
$3.44 Sentiment: Buy Disclosure: Held
